Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength
· cnbc.com · popularity 36/100 · 0 similar stories today
Read the original at cnbc.com →
Summary
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
Found in: CNBC Top News. Rating basis: single outlet; outlet tier 5; 1 feeds; feed position 16.